Taysha Gene Therapies
Gerald S. Lipshutz, M.D., M.S., is a Professor-in-Residence in the Departments of Surgery and Molecular and Medical Pharmacology, Surgical Director of the Pancreas/Auto-islet Transplant Program, and Chairman of the Academic Medicine College at the David Geffen School of Medicine at University of California, Los Angeles. His clinical specialties and interests include liver and pancreas transplantation and gene and cell therapies for single-gene metabolic disorders of the liver. Dr. Lipshutz is a grant reviewer for the Wellcome Trust and the US National Institutes of Health where he is a standing member of the GDD study section. He is a Principal Investigator at the UCLA Lipschutz Hepatic Regenerative Medical Laboratory and for several NIH-funded and industry-sponsored studies for gene therapies. He is the author of over 70 peer-reviewed articles and is an Editorial Board member of Molecular Therapy – Methods and Clinical Development and Gene Therapy.
Dr. Lipshutz earned his medical degree from the University of California, Los Angeles.
This person is not in the org chart
This person is not in any offices
Taysha Gene Therapies
Taysha Gene Therapies is on a mission to eradicate severe and life-threatening monogenic CNS disease. With a singular focus on developing curative medicines, they hope to rapidly translate their treatments from bench to bedside.